The present invention provides a compound of the Formula (I): wherein X, R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, and R.sup.9 are as defined herein, or a pharmaceutically acceptable salt thereof. ##STR00001##

The present invention provides a compound of the Formula (I): wherein X, R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, and R.sup.9 are as defined herein, or a pharmaceutically acceptable salt thereof. ##STR00001##

The disclosure generally relates to a process for the preparation of compounds of formula I, including synthetic intermediates which are useful in the process. ##STR00001##

The disclosure generally relates to a process for the preparation of compounds of formula I, including synthetic intermediates which are useful in the process. ##STR00001##

Provided is an organic light emitting element having stable performance in the air. The organic light emitting element includes: an anode; a cathode; and a first organic compound layer placed between the anode and the cathode, in which: the organic light emitting element further includes a first organic compound layer placed between the cathode and the emission layer, and a second organic compound layer placed between the emission layer and the first organic compound layer, and brought into contact with the first organic compound layer; the first organic compound layer contains a first organic compound; the second organic compound layer contains a second organic compound; and the first organic compound includes an organic compound represented by the following general formula [1], and the second organic compound includes an organic compound different from the first organic compound ##STR00001##

Provided is an organic light emitting element having stable performance in the air. The organic light emitting element includes: an anode; a cathode; and a first organic compound layer placed between the anode and the cathode, in which: the organic light emitting element further includes a first organic compound layer placed between the cathode and the emission layer, and a second organic compound layer placed between the emission layer and the first organic compound layer, and brought into contact with the first organic compound layer; the first organic compound layer contains a first organic compound; the second organic compound layer contains a second organic compound; and the first organic compound includes an organic compound represented by the following general formula [1], and the second organic compound includes an organic compound different from the first organic compound ##STR00001##

A condensed-cyclic compound of Formula 1: ##STR00001##
wherein, in Formula 1, groups X.sub.1, X.sub.11 to X.sub.14, L.sub.21, L.sub.22, R.sub.21, and R.sub.21, and variables a21, a22, b21, b22, c21, and c22 are described in the specification.

A condensed-cyclic compound of Formula 1: ##STR00001##
wherein, in Formula 1, groups X.sub.1, X.sub.11 to X.sub.14, L.sub.21, L.sub.22, R.sub.21, and R.sub.21, and variables a21, a22, b21, b22, c21, and c22 are described in the specification.

The present disclosure provides for a compound according to formula (I)

##STR00001##

or a pharmaceutically acceptable salt thereof as Ca.sub.V1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.

The present disclosure provides for a compound according to formula (I)

##STR00001##

or a pharmaceutically acceptable salt thereof as Ca.sub.V1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.